Neue Perspektiven für die Antikoagulation bei Vorhofflimmern

Literatur

• 1 Ansell J, Hirsh J, Hylek E. et al . Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).  Chest. 2008;  133 160S-198S
  Google Scholar
• 2 Camm A J, Kirchhof P, Lip G Y. et al . Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC).  Europace. 2010;  12 1360-1420
  Google Scholar
• 3 Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.  BMJ (Clinical research ed). 2002;  324 71-86
  Google Scholar
• 4 Connolly S, Pogue J, Hart R. et al . Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial.  Lancet. 2006;  367 1903-1912
  Google Scholar
• 5 Connolly S J, Eikelboom J, Joyner C. et al . Apixaban in patients with atrial fibrillation.  The New England journal of medicine. 2011;  364 806-817
  Google Scholar
• 6 Connolly S J, Ezekowitz M D, Yusuf S. et al . Dabigatran versus warfarin in patients with atrial fibrillation.  The New England journal of medicine. 2009;  361 1139-1151
  Google Scholar
• 7 Connolly S J, Ezekowitz M D, Yusuf S. et al . Newly identified events in the RE-LY trial.  The New England journal of medicine. 2010;  363 1875-1876
  Google Scholar
• 8 Connolly S J, Pogue J, Hart R G. et al . Effect of clopidogrel added to aspirin in patients with atrial fibrillation.  The New England journal of medicine. 2009;  360 2066-2078
  Google Scholar
• 9 Diener H C, Connolly S J, Ezekowitz M D. et al . Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial.  Lancet neurology. 2010;  9 1157-1163
  Google Scholar
• 10 Eriksson B I, Dahl O E, Rosencher N. et al . Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial.  Lancet. 2007;  370 949-956
  Google Scholar
• 11 Granger C B, Alexander J H, McMurray J J. et al . Apixaban versus Warfarin in Patients with Atrial Fibrillation.  N Engl J Med. 2011;  online publication 28. August
  Google Scholar
• 12 Lip G Y, Hart R G, Conway D S. Antithrombotic therapy for atrial fibrillation.  BMJ (Clinical research ed). 2002;  325 1022-1025
  Google Scholar
• 13 Patel M R, Mahaffey K W, Garg J. et al . Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation.  N Engl J Med. 2011;  published online in August 2011
  Google Scholar
• 14 Turpie A G, Lassen M R, Eriksson B I. et al . Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty. Pooled analysis of four studies.  Thrombosis and haemostasis. 2011;  105 444-453
  Google Scholar
• 15 Wallentin L, Yusuf S, Ezekowitz M D. et al . Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial.  Lancet. 2010;  376 975-983
  Google Scholar

Prof. Dr. Martin Moser

Innere Medizin III (Kardiologie und Angiologie)
Universitätsklinik Freiburg

Hugstetter Strasse 55

79106 Freiburg

Email: martin.moser@uniklinik-freiburg.de